Evidence from preclinical models highlights that modulating specific eCBS targets—such as CB1, CB2, FAAH, and MAGL—can attenuate drug-induced neurotoxicity and ameliorate neuropathological features of Alzheimer’s, Parkinson’s, Huntington’s, and motor neuron diseases (Figure 5). This evidence concerns the gene MGLL and motor neuron disorder.